Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/24/2023* 16:30 EST Earnings Call Q4 2022 -- -- --
02/24/2023* -- Results Q4 2022 -- -1.48 --
11/08/2022 16:30 EST Earnings Call Q3 2022 -- -- --
11/08/2022 -- Results Q3 2022 -1.25 -1.44 13.19%
08/04/2022 16:30 EST Earnings Call Q2 2022 -- -- --
08/04/2022 -- Results Q2 2022 -1.50 -1.50 -0.10%
05/05/2022 16:30 EST Earnings Call Q1 2022 -- -- --
05/05/2022 -- Results Q1 2022 -1.45 -1.52 4.40%
*Estimated Date/Time

Earnings

Next Report Date 02/24/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/08/2022
Beat/Miss Upgrade
Return Since -12.37%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result.
URL https://www.natera.com
Investor Relations URL https://investor.natera.com
HQ State/Province Texas
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Growth
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
--
8.43%
-23.23%
55.28%
141.3%
195.4%
-6.16%
-60.18%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-15.74%
--
--
--
--
--
54.43%
18.78%
-27.31%
-58.68%
-88.50%
-99.97%
-99.39%
-89.16%
-15.67%
-56.75%
-64.26%
-44.02%
-2.15%
19.27%
24.31%
-52.35%
107.0%
-47.43%
-67.30%
38.79%
-10.12%
-45.41%
-76.01%
-54.39%
38.08%
-28.97%
-63.53%
As of November 29, 2022.

Profile

Edit
Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing the genetic features of a fetus. Natera's array of diagnostic services includes Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic, or a patient for the test upon delivery of the test result.
URL https://www.natera.com
Investor Relations URL https://investor.natera.com
HQ State/Province Texas
Sector Healthcare
Industry Diagnostics & Research
Equity Style Small Cap/Growth
Next Earnings Release Feb. 24, 2023 (est.)
Last Earnings Release Nov. 08, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
AOFCX 121.99M USD 3.86%
FRTY 1.193M USD 3.74%
GNOM 6.506M USD 3.26%
ASPYX 99.16M USD 2.50%
ATFV 205463.0 USD 2.07%
CCRIX 24.73M USD 1.71%
LIACX 41.30M USD 1.63%
HAPY 83797.00 USD 1.23%
ACIZX 28.84M USD 1.18%
GTSDX 24.50M USD 1.08%
BTEC 537631.0 USD 0.99%
BBH 3.703M USD 0.73%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter NTRA Tweets